Does Rallies show Form 4 insider transactions for ATRA?

Yes. Rallies tracks ATRA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ATRA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ATRA. It does not provide personalized investment advice.

ATRA (Atara Biotherapeutics, Inc) Stock Analysis - Insider Trades

Atara Biotherapeutics, Inc (ATRA) is a publicly traded Healthcare sector company. As of May 21, 2026, ATRA trades at $9.34 with a market cap of $82.44M and a P/E ratio of 3.63. ATRA moved +0.96% today. Year to date, ATRA is -43.95%; over the trailing twelve months it is +35.00%. Its 52-week range spans $3.92 to $19.15. Analyst consensus is buy with an average price target of $15.50. Rallies surfaces ATRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ATRA stock inside the company?

Recent ATRA insider activity includes Nguyen AnhCo sold 5.24K, Grant-Huerta Yanina sold 2.41K, Panacea Innovation Ltd sold 313.45K, EcoR1 Capital, LLC bought 507.41K, and Grant-Huerta Yanina sold 24. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ATRA Key Metrics

Key financial metrics for ATRA
Metric	Value
Price	$9.34
Market Cap	$82.44M
P/E Ratio	3.63
EPS	$2.61
Dividend Yield	0.00%
52-Week High	$19.15
52-Week Low	$3.92
Volume	34
Avg Volume	0
Revenue (TTM)	$120.77M
Net Income	$32.69M
Gross Margin	0.00%

Recent ATRA Insider Trades

Nguyen AnhCo sold 5.24K (~$47.84K) on May 18, 2026.
Grant-Huerta Yanina sold 2.41K (~$22.04K) on May 18, 2026.
Panacea Innovation Ltd sold 313.45K (~$3.17M) on May 7, 2026.
EcoR1 Capital, LLC bought 507.41K (~$4.74M) on May 7, 2026.
Grant-Huerta Yanina sold 24 (~$121.848) on Mar 2, 2026.

Latest ATRA News

Atara Biotherapeutics Upgraded to Buy with $13 Target After FDA Clears Tabelecleucel Path — May 8, 2026
Atara Secures FDA Resubmission Path for Tabelecleucel BLA, Preserves Review Timeline — May 7, 2026
Atara Seeks FDA Type A Meeting, Submits Efficacy Data for Tab-cel Resubmission — Mar 3, 2026

ATRA Analyst Consensus

2 analysts cover ATRA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.50.

Common questions about ATRA

Who is trading ATRA stock inside the company?: Recent ATRA insider activity includes Nguyen AnhCo sold 5.24K, Grant-Huerta Yanina sold 2.41K, Panacea Innovation Ltd sold 313.45K, EcoR1 Capital, LLC bought 507.41K, and Grant-Huerta Yanina sold 24. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ATRA?: Yes. Rallies tracks ATRA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ATRA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ATRA. It does not provide personalized investment advice.